ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation (ENVISION)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05932615 |
Recruitment Status :
Recruiting
First Posted : July 6, 2023
Last Update Posted : April 30, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Aortic Valve Stenosis Heart Valve Diseases Aortic Valve Disease Heart Disease Structural Disorder | Device: Navitor Transcatheter Aortic Valve Implantation (TAVI) System Device: Any Commercially Available Transcatheter Aortic Valve (CAV) System | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1500 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement |
Actual Study Start Date : | March 19, 2024 |
Estimated Primary Completion Date : | April 2027 |
Estimated Study Completion Date : | April 2036 |
Arm | Intervention/treatment |
---|---|
Experimental: Navitor Transcatheter Aortic Valve Implantation (TAVI) System
TAVI with Abbott Navitor Transcatheter Aortic Valve Implantation (TAVI) System
|
Device: Navitor Transcatheter Aortic Valve Implantation (TAVI) System
TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy. |
Active Comparator: Any Commercially Available Transcatheter Aortic Valve System (CAV)
TAVI with any FDA approved commercially available Transcatheter Aortic Valve System (CAV)
|
Device: Any Commercially Available Transcatheter Aortic Valve (CAV) System
TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy. |
- Composite of all-cause mortality or all stroke [ Time Frame: At 12 months post-procedure ]Number of patients that had any of the outcome events.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
-
Subject who is deemed to be at intermediate or low risk for open surgical aortic valve replacement:
- Intermediate risk: estimated risk of overall surgical mortality ≥ 3% and < 8% at 30 days
- Low risk: estimated risk of overall surgical mortality < 3% at 30 days Estimated risk of overall surgical mortality includes consideration of the Society of Thoracic Surgeons (STS) risk score, overall clinical status, and other clinical co-morbidities unmeasured by the risk calculator
- New York Heart Association (NYHA) Functional Classification of II, III, or IV
- Degenerative aortic valve stenosis
Key Exclusion Criteria:
- In the opinion of the Investigator, life expectancy is less than 2 years
- Evidence of an acute myocardial infarction [defined as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) with acute ischemia symptoms and troponin elevation] within 30 days prior to index procedure
- Untreated clinically significant coronary artery disease requiring revascularization
- Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior (except pacemaker or implantable cardioverter defibrillator (ICD) implant) to index procedure or planned within 30 days following the index procedure
- Blood dyscrasias as defined: leukopenia (WBC < 3000 mm3), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count < 50,000 cells/mm³); history of bleeding diathesis or coagulopathy
- Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that would preclude anticoagulation
- Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA)
- Renal insufficiency (creatinine > 3.0 mg/dL or eGFR < 30 ml/min/1.73m2) and/or end stage renal disease requiring chronic dialysis
- Hostile chest or conditions or complications from prior surgery that would make the subject be considered high surgical risk (i.e., mediastinitis, radiation damage, abnormal chest wall, porcelain aorta, adhesion of aorta or internal mammary artery to sternum, etc.)
- Significant frailty as determined by the heart team (after objective assessment of frailty parameters) that would indicate high or extreme surgical risk
- Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+)
- Aortic valve is a unicuspid or bicuspid valve as verified by echocardiography or CT.
- Severe ventricular dysfunction with LVEF < 30% as measured by resting echocardiogram
- Pre-existing prosthetic heart valve or other implant (such as prosthetic ring or transcatheter edge-to-edge repair (TEER) clip) in any valve position
- Severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the left ventricular outflow tract (LVOT)
- Severe (greater than or equal to 3+) mitral regurgitation or severe mitral stenosis
- Minimum access vessel diameter of < 5.0 mm for small FlexNav Delivery System and < 5.5 mm for large FlexNav Delivery System
- Eccentricity ratio of the annulus < 0.73
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05932615
Contact: Sara Scrivano | 623-256-9821 | sara.scrivano@abbott.com | |
Contact: Alicia Kimber | 415-917-9696 | alicia.kimber@abbott.com |
Study Director: | Vinny Podichetty | Abbott Structural Heart | |
Study Chair: | Michael Reardon, MD | The Methodist Hospital Research Institute | |
Study Chair: | Azeem Azeem, MD | Montefiore Medical Center | |
Principal Investigator: | Bassem Chehab, MD | Cardiovascular Research Institute of Kansas | |
Principal Investigator: | Ibrahim Sultan, MD | The University of Pittsburgh Medical Center |
Responsible Party: | Abbott Medical Devices |
ClinicalTrials.gov Identifier: | NCT05932615 |
Other Study ID Numbers: |
ABT-CIP-10487 |
First Posted: | July 6, 2023 Key Record Dates |
Last Update Posted: | April 30, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There is not a plan to make IPD available to other researhers. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
NAVITOR Heart disease Transcatheter aortic valve implantation (TAVI) Aortic stenosis Cardiovascular diseases |
Heart Diseases Aortic Valve Stenosis Aortic Valve Disease Heart Valve Diseases |
Constriction, Pathologic Cardiovascular Diseases Pathological Conditions, Anatomical Ventricular Outflow Obstruction |